This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Gongwin Biopharm Co., Ltd. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Di-Rong Chen: Innovator in Pharmaceutical Compositions
Introduction
Di-Rong Chen is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of melanoma and fat reduction.
Latest Patents
Di-Rong Chen holds 2 patents that showcase his innovative approaches. His first patent is a method for treating melanoma, which includes a pharmaceutical composition featuring a benzenesulfonamide derivative and a pharmaceutically acceptable carrier. This method involves administering the composition to a subject in need and highlights the use of the pharmaceutical composition in the manufacture of a medicament for treating melanoma. His second patent focuses on reducing fat by administering benzenesulfonamide compositions. This composition also includes a benzenesulfonamide derivative and a pharmaceutically or cosmetically acceptable carrier. The method aims for fat ablation or lipolysis and addresses the prevention or treatment of diseases related to fat accumulation.
Career Highlights
Di-Rong Chen is associated with Gongwin Biopharm Co., Ltd., where he continues to develop innovative solutions in the pharmaceutical industry. His work is characterized by a commitment to improving health outcomes through scientific advancements.
Collaborations
Di-Rong Chen collaborates with esteemed colleagues, including Chuan-Ching Yang and Mao-Yuan Lin, to further enhance the impact of his research and inventions.
Conclusion
Di-Rong Chen's contributions to pharmaceutical innovations, particularly in treating melanoma and fat reduction, underscore his role as a significant inventor in the field. His work continues to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile